Structural chemistry of human SET domain protein methyltransferases

Current Chemical Genomics

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 85-94

  Schapira, Matthieu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epigenetics; Histone; Methyltransferase; Pmt; Set domain; Structure

Indexed keywords

BIX 01294; E 67; E 72; METHYLTRANSFERASE INHIBITOR; PROTEIN METHYLTRANSFERASE; S ADENOSYLMETHIONINE; SYNEFUNGIN; UNC 0224; UNC 0638; UNCLASSIFIED DRUG;

BINDING SITE; CATALYSIS; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; ENTHALPY; HUMAN; HUMAN GENOME; IC 50; MOLECULAR DOCKING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SET DOMAIN;

EID: 80455125845     PISSN: None     EISSN: 18753973     Source Type: Journal    
DOI: 10.2174/1875397301005010085     Document Type: Review

References (45)

1. Fischle W, Wang Y, Allis CD. Binary switches and modification cassettes in histone biology and beyond. Nature 2003; 425: 475-9.
2. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
3. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009; 8: 724-32.
4. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005; 6: 838-49.
5. Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem Sci 2003; 28: 329-35.
6. Petrossian TC, Clarke SG. Uncovering the human methyltransferasome. Mol Cell Proteomics 2011; 10: M110 000976.
7. Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett 2010; [Epub ahead of print].
8. Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 2009; 1789: 45-57.
9. Spannhoff A, Hauser AT, Heinke R, Sippl W, Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 2009; 4: 1568-82.
10. Volkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie 2007; 89: 1-20.
11. Min J, Feng Q, Li Z, Zhang Y, Xu RM. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003; 112: 711-23.
12. Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 2005; 6: 227.
13. Qian C, Zhou MM. SET domain protein lysine methyltransferases: Structure, specificity and catalysis. Cell Mol Life Sci 2006; 63: 2755-63.
14. Xiao B, Jing C, Wilson JR, et al. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 2003; 421: 652-6.
15. Han Z, Xing X, Hu M, Zhang Y, Liu P, Chai J. Structural basis of EZH2 recognition by EED. Structure 2007; 15: 1306-15.
16. Collins RE, Northrop JP, Horton JR, et al. The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules. Nat Struct Mol Biol 2008; 15: 245-50.
17. Huang J, Dorsey J, Chuikov S, et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem 2010; 285: 9636-41.
18. Wu H, Min J, Lunin VV, et al. Structural biology of human H3K9 methyltransferases. PLoS One 2010; 5: e8570.
19. Couture JF, Collazo E, Brunzelle JS, Trievel RC. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev 2005; 19: 1455-65.
20. Xiao B, Jing C, Kelly G, et al. Specificity and mechanism of the histone methyltransferase Pr-Set7. Genes Dev 2005; 19: 1444-54.
21. Southall SM, Wong PS, Odho Z, Roe SM, Wilson JR. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell 2009; 33: 181-91.
22. Sirinupong N, Brunzelle J, Doko E, Yang Z. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3. J Mol Biol 2011; 406(1): 149-59.
23. Sirinupong N, Brunzelle J, Ye J, Pirzada A, Nico L, Yang Z. Crystal structure of cardiac-specific histone methyltransferase SmyD1 reveals unusual active site architecture. J Biol Chem 2010; 285: 40635-44.
24. Wang M, Mok MW, Harper H, et al. Structural genomics of histone tail recognition. Bioinformatics 2010; 26: 2629-30.
25. Liu F, Chen X, Allali-Hassani A, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem 2009; 52: 7950-3.
26. Chang Y, Zhang X, Horton JR, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 2009; 16: 312-7.
27. Couture JF, Collazo E, Hauk G, Trievel RC. Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol 2006; 13: 140-6.
28. Rathert P, Dhayalan A, Murakami M, et al. Protein lysine methyltransferase G9a acts on non-histone targets. Nat Chem Biol 2008; 4: 344-6.
29. Binda O, LeRoy G, Bua DJ, Garcia BA, Gozani O, Richard S. Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: regulation of lysine methyltransferases by physical interaction with their substrates. Epigenetics 2010; 5: 767-75.
30. Kwon T, Chang JH, Kwak E, et al. Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J 2003; 22: 292-303.
31. Wilson JR, Jing C, Walker PA, et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell 2002; 111: 105-15.
32. Guo HB, Guo H. Mechanism of histone methylation catalyzed by protein lysine methyltransferase SET7/9 and origin of product specificity. Proc Natl Acad Sci U S A 2007; 104: 8797-802.
33. Collins RE, Tachibana M, Tamaru H, et al. In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases. J Biol Chem 2005; 280: 5563-70.
34. Couture JF, Dirk LM, Brunzelle JS, Houtz RL, Trievel RC. Structural origins for the product specificity of SET domain protein methyltransferases. Proc Natl Acad Sci U S A 2008; 105: 20659-64.
35. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117(8): 2451-9.
36. Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010; 107: 20980-5.
37. Zhang X, Yang Z, Khan SI, et al. Structural basis for the product specificity of histone lysine methyltransferases. Mol Cell 2003; 12: 177-85.
38. Chang Y, Ganesh T, Horton JR, et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J Mol Biol 2010; 400: 1-7.
39. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007; 25: 473-81.
40. Vedadi M, Barsyte-Lovejoy D, Liu F, et al. UNC0638: Potent, selective, and cell-penetrant chemical probe of protein lysine methyltransferases G9a and GLP. Nat Chem Biol 2011; in press.
41. Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 2009; 49(2): 377-89.
42. Campagna-Slater V, Mok MW, Nguyen KT, Feher M, Najmanovich R, Schapira M. Structural chemistry of the histone methyltransferases cofactor binding site. J Chem Inf Model 2011; 51(3): 612-23.
43. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005; 1: 143-5.
44. Dowden J, Hong W, Parry RV, Pike RA, Ward SG. Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg Med Chem Lett 2010; 20: 2103-5.
45. Spannhoff A, Machmur R, Heinke R, et al. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 2007; 17: 4150-3.